EXCLUSIVE ONLINE CONTENT
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
Revive Therapeutics Ltd. recently announced it has filed an application with the US FDA to receive Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver….
Diffusion Pharmaceuticals Inc. recently announced it has dosed the first participants in its Altitude Trial. The trial will evaluate the company’s lead product candidate, trans sodium crocetinate (TSC)….
Decibel Therapeutics Announces Extension of Research Term Under Strategic Collaboration With Regeneron to Discover & Develop Gene Therapies for Hearing Loss
Decibel Therapeutics recently announced that Regeneron has extended the research term of its collaboration with the company to discover and develop gene therapies for hearing loss…..
Cytovia & Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Cytovia Therapeutics, Inc. and Cellectis recently announced they have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and….
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing & Manufacturing Next-Generation COVID-19 Vaccines
ImmunityBio, Inc. recently announced the expansion of the company’s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA), recombinant protein vaccine candidates, and potent adjuvant formulations that….